Active	Status	Sponsor type	Region	Phase	Filter
25 Active 3 Inactive 28 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

19 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chang, Jessica
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Kossler, Andrea
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Active, not recruiting	4	313	Europe, US	Teprotumumab, TEPEZZA, Placebo, Saline Solution	Amgen	Thyroid Eye Disease	04/26	04/26
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies	Recruiting	3	143	Europe, US	Intervention/Treatment	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/25	03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)	Active, not recruiting	3	188	Europe, US, RoW	Veligrotug (VRDN-001), Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	12/24	09/25
Kashani, Amir H
SyncAV, NCT04100148: Post-Market Trial	Active, not recruiting	N/A	1686	Europe, Canada, Japan, US, RoW	SyncAV programmed ON, Fixed AV delay	Abbott Medical Devices	Congestive Heart Failure	06/25	12/25
NCT05809596: HEAL-LAA Clinical Trial	Active, not recruiting	N/A	949	US	WATCHMAN FLX Pro LAAC Device, Left Atrial Appendage Closure	Boston Scientific Corporation	Atrial Fibrillation, Bleeding, Stroke	07/24	08/25
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC	Recruiting	N/A	2650	Europe, Canada, Japan, US, RoW	Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC	Abbott Medical Devices	Atrial Fibrillation, Stroke, Bleeding	08/27	08/30
Zhang-Nunes, Sandy
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study	Active, not recruiting	4	313	Europe, US	Teprotumumab, TEPEZZA, Placebo, Saline Solution	Amgen	Thyroid Eye Disease	04/26	04/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Zhang, Sandy X
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Angell, Trevor E
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Gokoffski, Kimberly K
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Leibowitz, Steven
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies	Recruiting	3	143	Europe, US	Intervention/Treatment	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/25	03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)	Active, not recruiting	3	188	Europe, US, RoW	Veligrotug (VRDN-001), Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	12/24	09/25
Jain, Amy Patel
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies	Recruiting	3	143	Europe, US	Intervention/Treatment	Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/25	03/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)	Active, not recruiting	3	188	Europe, US, RoW	Veligrotug (VRDN-001), Placebo	Viridian Therapeutics, Inc.	Thyroid Eye Disease	12/24	09/25